Suppr超能文献

组蛋白去乙酰化酶2通过上调纤连蛋白促进非小细胞肺癌细胞的迁移和侵袭。

HDAC2 promotes the migration and invasion of non-small cell lung cancer cells via upregulation of fibronectin.

作者信息

Li Li, Mei Dr Tonghua, Zeng Yun

机构信息

Department of Respiratory Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, PR China.

Department of Respiratory Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, PR China.

出版信息

Biomed Pharmacother. 2016 Dec;84:284-290. doi: 10.1016/j.biopha.2016.09.030. Epub 2016 Sep 22.

Abstract

Recent studies indicated that histone deacetylases (HDACs) can modulate the tumorigenesis and development of cancer cells. We evaluated the expression of class I HDACs in non-small cell lung cancer (NSCLC) cells and found that HDAC2 was significantly increased in NSCLC cells as compared with the normal bronchial epithelial cell line BEAS-2B. Silencing of HDAC2 by its specific siRNAs can significantly inhibit the in vitro migration and invasion of A549 and H1395 cells. While over expression of HDAC2 by transfection of pcDNA/HDAC2 plasmid can trigger the motility of NSCLC cells. Over expression of HDAC2 increased the protein and mRNA expression of firbronectin (FN), which can accelerate the metastasis of cancer cells. Similarly, knock down of HDAC2 suppressed the expression of FN. The inhibitor of NF-κB, while not ERK1/2 or PI3K/Akt, attenuated HDAC2 induced up regulation of FN and invasion of NSCLC cells. Furthermore, HDAC2 can markedly increase both mRNA and protein levels of p65 in NSCLC cells. Collectively, our data revealed that HDAC2 can trigger migration and invasion of NSCLC cells via up regulation FN through activation of NF-κB. It suggested HDAC2 might be a potential therapeutic target for the drug development of NSCLC patients.

摘要

近期研究表明,组蛋白去乙酰化酶(HDACs)可调控癌细胞的肿瘤发生与发展。我们评估了I类HDACs在非小细胞肺癌(NSCLC)细胞中的表达,发现与正常支气管上皮细胞系BEAS-2B相比,NSCLC细胞中HDAC2显著增加。通过其特异性小干扰RNA(siRNAs)沉默HDAC2可显著抑制A549和H1395细胞的体外迁移和侵袭。而转染pcDNA/HDAC2质粒过表达HDAC2可引发NSCLC细胞的运动性。HDAC2过表达增加了纤连蛋白(FN)的蛋白质和mRNA表达,这可加速癌细胞的转移。同样,敲低HDAC2可抑制FN的表达。NF-κB抑制剂而非ERK1/2或PI3K/Akt抑制剂可减弱HDAC2诱导的FN上调和NSCLC细胞的侵袭。此外,HDAC2可显著增加NSCLC细胞中p65的mRNA和蛋白质水平。总体而言,我们的数据表明HDAC2可通过激活NF-κB上调FN来触发NSCLC细胞的迁移和侵袭。这表明HDAC2可能是NSCLC患者药物开发的潜在治疗靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验